cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Liat® System— 510(k) K223591

Substantially Equivalent

Roche Molecular Systems, Inc.

FDA 510(k) clearance K223591 for cobas® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the cobas® Liat® System, Substantially Equivalent on 2023-07-27. Applicant: Roche Molecular Systems, Inc..

Clearance details

Applicant
Roche Molecular Systems, Inc.
Product code
Code QOF
Advisory panel
Microbiology
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Dual Track
Location
Pleasanton, CA, US
Download summary PDFView on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.